Copyright
©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Dec 7, 2013; 19(45): 8335-8341
Published online Dec 7, 2013. doi: 10.3748/wjg.v19.i45.8335
Published online Dec 7, 2013. doi: 10.3748/wjg.v19.i45.8335
Table 1 Baseline characteristics of patients with ulcerative colitis
Mild-to-moderate1 | Severe | P value | |
Age upon entry, yr (mean ± SD) | 39.3 ± 12.5 | 40.0 ± 19.7 | > 0.2 |
Gender, male/female | 6/5 | 7/0 | > 0.2 |
Extent of disease | |||
Number of patients | > 0.2 | ||
Extensive | 7 | 7 | |
Left-side | 4 | 0 | |
Proctitis | 0 | 0 | |
Concomitant medication use | |||
Number of patients | > 0.2 | ||
Sulfasalazine | 3 | 0 | |
5-ASA | 9 | 7 | |
Glucocorticoid | 6 | 2 | |
Immunomodulator | 1 | 0 |
Table 2 Sensitivity and specificity of procalcitonin and C-reactive protein for severe ulcerative colitis detection
Marker | Sensitivity | 95%CI | Specificity | 95%CI |
Procalcitonin (ng/mL) | ||||
> 0.0250 | 100% | 59.04-100.0 | 27.27% | 6.022-60.97 |
> 0.0400 | 100% | 59.04-100.0 | 72.73% | 39.03-93.98 |
> 0.0550 | 100% | 59.04-100.0 | 100% | 71.51-100.0 |
> 0.0650 | 71.43% | 29.04-96.33 | 100% | 71.51-100.0 |
> 0.0850 | 57.14% | 18.41-90.10 | 100% | 71.51-100.0 |
> 0.1050 | 42.86% | 9.899-81.59 | 100% | 71.51-100.0 |
> 0.1150 | 28.57% | 3.669-70.96 | 100% | 71.51-100.0 |
> 0.1350 | 14.29% | 0.3610-57.87 | 100% | 71.51-100.0 |
C-reactive protein (mg/dL) | ||||
> 0.2500 | 100% | 59.04-100.0 | 27.27% | 6.022-60.97 |
> 0.5000 | 85.71% | 42.13-99.64 | 36.36% | 10.93-69.21 |
> 0.7000 | 85.71% | 42.13-99.64 | 45.45% | 16.75-76.62 |
> 0.9000 | 85.71% | 42.13-99.64 | 63.64% | 30.79-89.07 |
> 1.400 | 85.71% | 42.13-99.64 | 72.73% | 39.03-93.98 |
> 2.600 | 85.71% | 42.13-99.64 | 81.82% | 48.22-97.72 |
> 3.600 | 85.71% | 42.13-99.64 | 90.91% | 58.72-99.77 |
> 4.050 | 71.43% | 29.04-96.33 | 90.91% | 58.72-99.77 |
> 4.700 | 71.43% | 29.04-96.33 | 100% | 71.51-100.0 |
> 7.100 | 57.14% | 18.41-90.10 | 100% | 71.51-100.0 |
> 9.850 | 42.86% | 9.899-81.59 | 100% | 71.51-100.0 |
> 10.75 | 28.57% | 3.669-70.96 | 100% | 71.51-100.0 |
> 11.35 | 14.29% | 0.3610-57.87 | 100% | 71.51-100.0 |
> 11.35 | 14.29% | 0.3610-57.87 | 100% | 76.84-100.0 |
- Citation: Koido S, Ohkusa T, Takakura K, Odahara S, Tsukinaga S, Yukawa T, Mitobe J, Kajihara M, Uchiyama K, Arakawa H, Tajiri H. Clinical significance of serum procalcitonin in patients with ulcerative colitis. World J Gastroenterol 2013; 19(45): 8335-8341
- URL: https://www.wjgnet.com/1007-9327/full/v19/i45/8335.htm
- DOI: https://dx.doi.org/10.3748/wjg.v19.i45.8335